I run testosterone instead. Testosterone costs 1/3 the price, produces better results, and has established safety data. When you stop the SARM, your testosterone doesn’t bounce back immediately. If you’re using a SARM, you’re shutting down your testosterone production. The marketing premise—"androgens without the downsides"—is scientifically unfounded. Most SARMs achieve maybe 60-80% of testosterone’s activation intensity. A further investigation is necessary to fully understand ostarine metabolism, especially in regular users, and the toxicological relevance of the potential in vivo production of cyanophenol-sulfate. We suggest ostarine-glucuronide and hydroxybenzonitrile-ostarine-glucuronide (M4) in non-hydrolyzed urine and ostarine and hydroxybenzonitrile-ostarine (M9) in hydrolyzed urine as markers to document ostarine intake in doping. A total of ten metabolites produced by O-glucuronidation, hydroxylation, ether cleavage, dealkylation, and sulfation were identified with consistent results between in vitro and in vivo data. The metabolic profile of ostarine, a SARM doping agent, was investigated with ten-donor-pooled human hepatocyte incubations and urine samples from six ostarine-positive cases. The above PCT protocol was designed by Dr. Michael Scally, a hormone replacement specialist, who administered this trio to 19 hypogonadal men in a clinical trial. Our tests indicate that Clomid stimulates gonadotropin-releasing hormone (GnRH), which increases LH via the pituitary gland and enhances natural testosterone production. If a user is taking 20 mg/day of Nolvadex and endogenous levels are not improving after 2 weeks, an increased dose of 40 mg/day will be beneficial. In harsher cases of 60–70% drops in testosterone, users may opt for 40 mg/day of Nolvadex for 4 weeks, although this is an aggressive PCT and unnecessary for most Ostarine users. Some of the published benzimidazole compounds were characterized as potent and efficacious myoanabolic SARMs. ORX, T, TP, and CaP are abbrevations for orchidectomy, testosterone, testosterone propionate, and prostate cancer, respectively. Figure 5 illustrates how BMS obtained potent and selective SARM activity by simplifying the B-ring to a 5.5 bicyclic hydantoin, which has a hydroxyl substituent properly located to interact with N705 (contrast (25b) and (26)). Compound (20) (30 mg/kg) partially increased VP weight as compared to intact controls (70 mg/100 g vs. 94 mg/100 g), but demonstrated full osteoanabolic activity and hypermyoanabolic activity. S (16) was extensively characterized for its osteoanabolic activity by Hanada et al. Likewise, androgens are known to have a positive effect on BMD through increase in periosteal bone formation Hanada et al., 2003. The role of estrogens in maintaining bone mass in women is also crucial, as shown by the rapid decline in BMD in postmenopausal symptoms. These drugs increase bone mineral density (BMD) by inhibiting osteoclast activity Fisher et al., 1999. Preventing bone loss and increasing bone formation are two mechanisms of protecting against osteoporosis. Class III receptors are those for which ligands have not yet been identified, and are hence classified as "orphans". Of the 48 receptors, bind ligand with a characterized ligand binding domain (LBD). AR belongs to the largest class of DNA binding transcription factors, called nuclear receptors, comprised of 48 members Evans, 1988; Tsai and O'Malley, 1994. Efforts among the pharmaceutical and academic communities to discover SRMs for other receptors such as glucocorticoid receptor (SGRM) Link et al., 2005; Mohler, 2007a; Mohler, 2007b, progesterone receptor (SPRM) Tabata et al., 2003 and others are in progress. The most active androgen in prostate is DHT, which is formed by the 5α-reduction (5-α-reductase is expressed in prostate and skin) of testosterone, the most abundant circulating androgen. The proposed mechanisms for the tissue selectivity of SARMs include the role of 5α-reductase, tissue-specific expression of coregulators, differences in the complexes formed by AR in anabolic and androgenic tissues, and the tissue-specific role of intracellular signaling cascades. At the 27th Annual Meeting of the ASBMR (2005), Ke et al. reported osteoanabolic SARM activity for CE-590 (structure unknown), (unpublished data). Lilly scientists patented two distinct SARM templates, the N-arylpyrrolidines and the tetrahydrocarbazoles, along with in vivo demonstrations of tissue-selective myoanabolic activity. The effects of GSK2420A on the prostate are consistent with partial agonist activity, eliciting a 2-fold increase over vehicle (versus 7-fold stimulation for DHT (3 mg/kg)), and decreased prostate weight in intact rats (unpublished data). For instance, (30) is a 2-(2,2,2)-trifluoroethyl-benzimidazole which when dosed at 2 mg/kg supported 126% LA weight (compared to 1 mg/kg testosterone) with an ED50 of 0.03 mg/d, but with little stimulation of the prostate Ng et al., 2007a, demonstrating an activity profile comparable to other hyperanabolic SARMs. LH suppression may cause side effects, especially in elderly men, due to suppression of endogenous testosterone and subsequently estrogen levels, leading to detrimental effects on multiple organs systems including pro-osteoporotic changes in bone. The proliferative effects on the prostate and elevation of hematocrit remain drawbacks, however. Though megestrol causes weight gain, its antianabolic properties result in decrease in lean body mass despite weight gain Lambert et al., 2002. Cachexia often occurs in patients with AIDS, cancer, kidney disease, sepsis, and burns and is characterized by weight loss, muscle wasting, and decrease in appetite. Disease states that result in rapid loss of muscle are likely to show significant benefit from SARM treatment. Thus, clinical proof of the benefits of SARM treatment for improving strength exists and shows promise for treating age-related decline in muscle strength, as well as other related indications being pursued by Pharmacopeia (age-related functional decline) and Ligand Pharmaceuticals (frailty), both having completed Phase I trials.